{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T07:21:25Z","timestamp":1779002485608,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-026-10598-3","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:32:24Z","timestamp":1773034344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Transthyretin amyloid depletion therapy: lessons from the phase 2 trial of coramitug"],"prefix":"10.1007","volume":"31","author":[{"given":"Alexander H.","family":"Gunn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maira","family":"Haque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel G.","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Senthil","family":"Selvaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"10598_CR1","doi-asserted-by":"publisher","unstructured":"Chakrabartty A (2024) Structural basis for monoclonal antibody therapy for transthyretin amyloidosis. Pharmaceuticals (Basel) Sep 17(9). https:\/\/doi.org\/10.3390\/ph17091225","DOI":"10.3390\/ph17091225"},{"key":"10598_CR2","doi-asserted-by":"publisher","unstructured":"Kittleson MM, Ambardekar AV, Cheng RK et al (2025) Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC concise clinical guidance. J Am Coll Cardiol Oct 31. https:\/\/doi.org\/10.1016\/j.jacc.2025.09.004","DOI":"10.1016\/j.jacc.2025.09.004"},{"key":"10598_CR3","doi-asserted-by":"publisher","unstructured":"Vergaro G, Ferrari Chen YF, Ioannou A et al (2025) Current and emerging treatment options for transthyretin amyloid cardiomyopathy. Heart May 27. https:\/\/doi.org\/10.1136\/heartjnl-2024-325184","DOI":"10.1136\/heartjnl-2024-325184"},{"key":"10598_CR4","doi-asserted-by":"publisher","unstructured":"Fontana M, Aimo A, Emdin M et al (2025) Transthyretin amyloid cardiomyopathy: from cause to novel treatments. Eur Heart J Oct 1. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf667","DOI":"10.1093\/eurheartj\/ehaf667"},{"key":"10598_CR5","doi-asserted-by":"publisher","unstructured":"Fontana M, Garcia-Pavia P, Grogan M et al (2025) Coramitug, a humanized monoclonal antibody for the treatment of transthyretin amyloid cardiomyopathy: a phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled trial. Circulation Nov 10. https:\/\/doi.org\/10.1161\/circulationaha.125.077304","DOI":"10.1161\/circulationaha.125.077304"},{"issue":"8","key":"10598_CR6","doi-asserted-by":"publisher","first-page":"e012112","DOI":"10.1161\/circheartfailure.124.012112","volume":"18","author":"M Fontana","year":"2025","unstructured":"Fontana M, Berk JL, Drachman B et al (2025) Changing treatment landscape in transthyretin cardiac amyloidosis. Circ Heart Fail Aug 18(8):e012112. https:\/\/doi.org\/10.1161\/circheartfailure.124.012112","journal-title":"Circ Heart Fail Aug"},{"issue":"19","key":"10598_CR7","doi-asserted-by":"publisher","first-page":"13243","DOI":"10.1074\/jbc.M114.557231","volume":"9","author":"SA Planque","year":"2014","unstructured":"Planque SA, Nishiyama Y, Hara M et al (2014) Physiological IgM class catalytic antibodies selective for transthyretin amyloid. J Biol Chem May 9(19):13243\u201313258. https:\/\/doi.org\/10.1074\/jbc.M114.557231","journal-title":"J Biol Chem May"},{"issue":"23","key":"10598_CR8","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1056\/NEJMc2304584","volume":"8","author":"M Fontana","year":"2023","unstructured":"Fontana M, Gilbertson J, Verona G et al (2023) Antibody-Associated reversal of ATTR Amyloidosis-Related cardiomyopathy. N Engl J Med Jun 8(23):2199\u20132201. https:\/\/doi.org\/10.1056\/NEJMc2304584","journal-title":"N Engl J Med Jun"},{"issue":"14","key":"10598_CR9","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1182\/blood.2022019406","volume":"5","author":"MA Gertz","year":"2023","unstructured":"Gertz MA, Cohen AD, Comenzo RL et al (2023) Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial. Blood Oct 5(14):1208\u20131218. https:\/\/doi.org\/10.1182\/blood.2022019406","journal-title":"Blood Oct"},{"issue":"1","key":"10598_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12872-021-02407-6","volume":"13","author":"A Wechalekar","year":"2022","unstructured":"Wechalekar A, Antoni G, Al Azzam W et al (2022) Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label phase 2 study and an adjunctive immuno-PET imaging study. BMC Cardiovasc Disord Feb 13(1):49. https:\/\/doi.org\/10.1186\/s12872-021-02407-6","journal-title":"BMC Cardiovasc Disord Feb"},{"issue":"3","key":"10598_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1056\/NEJMoa2303765","volume":"20","author":"P Garcia-Pavia","year":"2023","unstructured":"Garcia-Pavia P, Aus dem Siepen F, Donal E et al (2023) Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid. N Engl J Med Jul 20(3):239\u2013250. https:\/\/doi.org\/10.1056\/NEJMoa2303765","journal-title":"N Engl J Med Jul"},{"issue":"2","key":"10598_CR12","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3109\/13506129.2016.1148025","volume":"23","author":"JN Higaki","year":"2016","unstructured":"Higaki JN, Chakrabartty A, Galant NJ et al (2016) Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin. Amyloid Jun 23(2):86\u201397. https:\/\/doi.org\/10.3109\/13506129.2016.1148025","journal-title":"Amyloid Jun"},{"issue":"1","key":"10598_CR13","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/13506129.2024.2420809","volume":"32","author":"OB Suhr","year":"2025","unstructured":"Suhr OB, Grogan M, Silva AMD et al (2025) PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study. Amyloid Mar 32(1):14\u201321. https:\/\/doi.org\/10.1080\/13506129.2024.2420809","journal-title":"Amyloid Mar"},{"issue":"14","key":"10598_CR14","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","volume":"1","author":"A Ioannou","year":"2024","unstructured":"Ioannou A, Cappelli F, Emdin M et al (2024) Stratifying disease progression in patients with cardiac ATTR amyloidosis. J Am Coll Cardiol Mar 1(14):1276\u20131291. https:\/\/doi.org\/10.1016\/j.jacc.2023.12.036","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10598_CR15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","volume":"11","author":"JD Gillmore","year":"2024","unstructured":"Gillmore JD, Judge DP, Cappelli F et al (2024) Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med Jan 11(2):132\u2013142. https:\/\/doi.org\/10.1056\/NEJMoa2305434","journal-title":"N Engl J Med"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10598-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10598-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10598-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:03:34Z","timestamp":1773079414000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10598-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10598"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10598-3","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review was conducted in accordance with established ethical standards for scholarly publications and the principles of the Declaration of Helsinki, where applicable. No human or animal subjects were involved and no ethics approval committee or IRB was applicable in this case.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declaration"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declarations"}},{"value":"Not applicable (this article does not involve human participants or the collection of individual data).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Dr. Selvaraj receives research support from the National Heart, Lung, and Blood Institute (K23HL161348 and 1R03HL180898-01), American Heart Association (#935275), American Academy of CME, Foundation for Sarcoidosis Research, and the Robert A. Winn Foundation Excellence in Clinical Trials. He consults for AstraZeneca and BridgeBio. Dr. Michel G Khouri reports institutional research support from Pfizer, BridgeBio Pharma, Alnylam Pharmaceuticals, and Ionis Pharmaceuticals; consulting\/advisory board support from BridgeBio Pharma and Alnylam Pharmaceuticals, and is a member of Alnylam Pharmaceuticals Speaker\u2019s Bureau.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"32"}}